Adam D. Pfefferle
Adam D. Pfefferle
Verified email at email.unc.edu - Homepage
Title
Cited by
Cited by
Year
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
PJ Roberts, JE Usary, DB Darr, PM Dillon, AD Pfefferle, MC Whittle, ...
Clinical cancer research 18 (19), 5290-5303, 2012
1422012
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
AB Hanker, AD Pfefferle, JM Balko, MG Kuba, CD Young, V Sánchez, ...
Proceedings of the National Academy of Sciences 110 (35), 14372-14377, 2013
1412013
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts
AD Pfefferle, JI Herschkowitz, J Usary, JC Harrell, BT Spike, JR Adams, ...
Genome biology 14 (11), 1-16, 2013
1352013
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma
W Liu, KB Monahan, AD Pfefferle, T Shimamura, J Sorrentino, KT Chan, ...
Cancer cell 21 (6), 751-764, 2012
1112012
Both noncoding and protein-coding RNAs contribute to gene expression evolution in the primate brain
CC Babbitt, O Fedrigo, AD Pfefferle, AP Boyle, JE Horvath, TS Furey, ...
Genome biology and evolution 2, 67-79, 2010
1102010
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer
R Nair, DL Roden, WS Teo, A McFarland, S Junankar, S Ye, A Nguyen, ...
Oncogene 33 (30), 3992-4002, 2014
882014
Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential
J Knezevic, AD Pfefferle, I Petrovic, SB Greene, CM Perou, JM Rosen
Oncogene 34 (49), 5997-6006, 2015
812015
Oncogenic PI3K mutations lead to NF-κB–dependent cytokine expression following growth factor deprivation
JE Hutti, AD Pfefferle, SC Russell, M Sircar, CM Perou, AS Baldwin
Cancer research 72 (13), 3260-3269, 2012
732012
Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver
MD Wallace, AD Pfefferle, L Shen, AJ McNairn, EG Cerami, BL Fallon, ...
Genetics 192 (2), 385-396, 2012
692012
Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis
JC Harrell, AD Pfefferle, N Zalles, A Prat, C Fan, A Khramtsov, OI Olopade, ...
Clinical & experimental metastasis 31 (1), 33-45, 2014
562014
Comparative expression analysis of the phosphocreatine circuit in extant primates: Implications for human brain evolution
AD Pfefferle, LR Warner, CW Wang, WJ Nielsen, CC Babbitt, O Fedrigo, ...
Journal of human evolution 60 (2), 205-212, 2011
412011
A potential role for glucose transporters in the evolution of human brain size
O Fedrigo, AD Pfefferle, CC Babbitt, R Haygood, CE Wall, GA Wray
Brain, behavior and evolution 78 (4), 315-326, 2011
392011
Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
AD Pfefferle, BT Spike, GM Wahl, CM Perou
Breast cancer research and treatment 149 (2), 425-437, 2015
292015
A pipeline to determine RT-QPCR control genes for evolutionary studies: application to primate gene expression across multiple tissues
O Fedrigo, LR Warner, AD Pfefferle, CC Babbitt, P Cruz-Gordillo, GA Wray
PLoS One 5 (9), e12545, 2010
272010
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling
CD Young, AD Pfefferle, P Owens, MG Kuba, BN Rexer, JM Balko, ...
Cancer research 73 (13), 4075-4085, 2013
242013
Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression
K Roarty, AD Pfefferle, CJ Creighton, CM Perou, JM Rosen
Oncogene 36 (43), 5958-5968, 2017
192017
Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers
AD Pfefferle, YN Agrawal, DC Koboldt, KL Kanchi, JI Herschkowitz, ...
Disease models & mechanisms 9 (7), 749-757, 2016
172016
Overview of genetically engineered mouse models of distinct breast cancer subtypes
J Usary, DB Darr, AD Pfefferle, CM Perou
Current protocols in pharmacology 72 (1), 14.38. 1-14.38. 11, 2016
152016
c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression
MA Cantrell, ND Ebelt, AD Pfefferle, CM Perou, CL Van Den Berg
Oncotarget 6 (14), 11863, 2015
102015
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer
DP Hollern, CM Contreras, S Dance-Barnes, GO Silva, AD Pfefferle, ...
Breast cancer research and treatment 174 (1), 143-155, 2019
42019
The system can't perform the operation now. Try again later.
Articles 1–20